Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results


BACKGROUND To report toxicity and early clinical outcomes of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery. METHODS Patients presenting early-stage breast cancer were enrolled in a phase II trial. ELIGIBILITY CRITERIA age > 18 years old… (More)
DOI: 10.1186/s13014-016-0701-z


4 Figures and Tables